These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 3163908)

  • 41. Comparison of the bactericidal activity of clindamycin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group.
    Stratton CW; Weeks LS; Aldridge KE
    Diagn Microbiol Infect Dis; 1991; 14(5):377-82. PubMed ID: 1797454
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro activity of Bay Y3118 against anaerobic bacteria.
    Wexler HM; Molitoris E; Finegold SM
    Antimicrob Agents Chemother; 1993 Nov; 37(11):2509-13. PubMed ID: 8285647
    [TBL] [Abstract][Full Text] [Related]  

  • 43. BMY28142, cefbuperazone (T-1982), and Sch 34343. Antimicrobial activity against 94 anaerobes compared to seven other antimicrobial agents.
    Jones RN; Barry AL; Packer RR
    Diagn Microbiol Infect Dis; 1985 May; 3(3):263-8. PubMed ID: 3838925
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative in vitro activity of BAY 12-8039 and five other antimicrobial agents against anaerobic bacteria.
    Edlund C; Sabouri S; Nord CE
    Eur J Clin Microbiol Infect Dis; 1998 Mar; 17(3):193-5. PubMed ID: 9665302
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effectiveness of cefotaxime alone and in combination with desacetylcefotaxime against Bacteroides fragilis.
    Wasilauskas BL
    Diagn Microbiol Infect Dis; 1989; 12(1):39-43. PubMed ID: 2714071
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro activities of three of the newer quinolones against anaerobic bacteria.
    Wexler HM; Molitoris E; Finegold SM
    Antimicrob Agents Chemother; 1992 Jan; 36(1):239-43. PubMed ID: 1317149
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Criteria for in vitro susceptibility testing of cefotetan. Correlations with clinical and bacteriologic responses.
    Barry AL
    Am J Surg; 1988 May; 155(5A):24-9. PubMed ID: 3287965
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro activity of cefotetan, a new cephamycin derivative, compared with that of other beta-lactam compounds.
    Wise R; Andrews JM; Hancox J
    Antimicrob Agents Chemother; 1982 Mar; 21(3):486-91. PubMed ID: 6954875
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anaerobic cocci and their resistance patterns to penicillin, cefoxitin, clindamycin and metronidazole: a Bulgarian study.
    Boyanova L; Osmanliev D; Petrov D; Mitov I; Usunova I; Petrov S; Minchev TZ
    Clin Microbiol Infect; 2000 Nov; 6(11):623-4. PubMed ID: 11168069
    [No Abstract]   [Full Text] [Related]  

  • 50. Comparative serum bactericidal activity of ceftizoxime/metronidazole, ceftizoxime, clindamycin, and imipenem against obligate anaerobic bacteria.
    Kowalsky SF; Echols RM; McCormick EM
    J Antimicrob Chemother; 1990 May; 25(5):767-75. PubMed ID: 2373663
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Differences in the in vitro inhibitory and bactericidal activity of ceftizoxime, cefoxitin, cefotetan, and penicillin G against Bacteroides fragilis group isolates. Comparison of time-kill kinetic studies with MIC values.
    Aldridge KE; Weeks LS; Stratton CW; Sanders CV
    Diagn Microbiol Infect Dis; 1990; 13(4):311-6. PubMed ID: 2076592
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antibacterial activity of cefminox against anaerobes.
    Watanabe K; Sawa K; Bunai M; Ueno K
    J Antibiot (Tokyo); 1985 May; 38(5):649-60. PubMed ID: 3874857
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vitro activity of BAY y 3118, and nine other antimicrobial agents against anaerobic bacteria.
    García-Rodríguez JA; García-Sánchez JE; Trujillano-Martín I; García-Sánchez E; García-García MI; Fresnadillo-Martínez MJ
    J Chemother; 1995 Jun; 7(3):189-96. PubMed ID: 7562012
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative susceptibility of anaerobic bacteria to ticarcillin, cefoxitin, metronidazole, and related antimicrobial agents.
    Henderson DK; Chow AW; Guze LB
    Antimicrob Agents Chemother; 1977 Apr; 11(4):679-82. PubMed ID: 856019
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro activity of cefbuperazone compared with that of other new beta-lactam agents against anaerobic gram-negative bacilli and contribution of beta-lactamase to resistance.
    Del Bene VE; Carek PJ; Twitty JA; Burkey LJ
    Antimicrob Agents Chemother; 1985 May; 27(5):817-20. PubMed ID: 3874597
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antimicrobial susceptibilities of anaerobic bacteria: recent clinical isolates.
    Staneck JL; Washington JA
    Antimicrob Agents Chemother; 1974 Sep; 6(3):311-5. PubMed ID: 15830478
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Susceptibility of anaerobic bacteria to tosufloxacin.
    Nord CE; Lindmark A; Persson I; Runow C
    Eur J Clin Microbiol Infect Dis; 1992 Mar; 11(3):263-5. PubMed ID: 1597207
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Susceptibility of anaerobic bacteria to antimicrobial agents.
    Collignon PJ; Munro R; Morris G
    Pathology; 1988 Jan; 20(1):48-52. PubMed ID: 3374973
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antibacterial activity of the cephamycin cefotetan: an in-vitro comparison with other beta-lactam antibiotics.
    Clarke AM; Zemcov SJ
    J Antimicrob Chemother; 1983 Jan; 11 Suppl():67-72. PubMed ID: 6404881
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro activity of cefoperazone/sulbactam and other antimicrobials against anaerobic bacteria.
    D'Amato RF; Hochstein L; Frankel H
    Diagn Microbiol Infect Dis; 1990; 13(1):51-5. PubMed ID: 2331850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.